Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study involves a treatment combination that includes Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone, known as D-VRd. Some participants will also receive a stem cell transplant, while others will receive additional treatment with Teclistamab and Talquetamab, which are newer therapies being explored for their effectiveness.

The purpose of the study is to use new methods to monitor the disease and understand how well these treatments work in patients who have not yet received any treatment for their multiple myeloma. Participants will receive the treatment over a period of time, and their response to the treatment will be closely monitored using advanced techniques to measure the presence of cancer cells in the blood and bone marrow. This will help researchers understand the effectiveness of the treatment combinations and the potential for achieving a state where no cancer cells are detectable.

The study will take place over several months, with regular check-ups and assessments to track the progress of the disease and the patient's response to the treatment. The goal is to gather information that could lead to better treatment strategies for multiple myeloma in the future. Participants will be monitored for any side effects or changes in their condition throughout the study period.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    Begin treatment with a combination of medications including daratumumab, bortezomib, lenalidomide, and dexamethasone. These medications are administered to manage multiple myeloma.

    Daratumumab is given as a subcutaneous injection. Bortezomib is also administered via subcutaneous injection. Lenalidomide and dexamethasone are taken orally in capsule form.

  2. Step 2

    Stem cell transplantation or alternative therapy

    For those eligible, an autologous stem cell transplantation (ASCT) may be performed. This involves using your own stem cells to help restore bone marrow function after high-dose chemotherapy.

    Alternatively, continue with the same combination of medications or switch to a new combination involving teclistamab and talquetamab if not undergoing transplantation.

  3. Step 3

    Consolidation therapy

    Following transplantation or alternative therapy, continue with the initial combination of medications to consolidate the treatment effects.

    This phase aims to further reduce the number of cancer cells and stabilize the disease.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring of minimal residual disease (MRD) is conducted using advanced techniques to assess the effectiveness of the treatment.

    MRD measurements are taken from bone marrow and peripheral blood to evaluate the presence of cancer cells.

  5. Step 5

    Completion of treatment

    The treatment course is completed after the specified number of cycles, which may vary depending on the treatment plan and response.

    Ongoing assessments will determine the overall response and any further treatment needs.

Who can join the trial?

12 criteria

  • Age between 18 and 70 years old.
  • Must have a new diagnosis of Multiple Myeloma (MM) according to specific criteria.
  • Must have measurable disease, which means certain levels of specific proteins in the blood or urine.
  • Must be newly diagnosed and not have received treatment before, with a plan to undergo high-dose therapy and a procedure called autologous stem cell transplantation.
  • Must have a performance status score of 0, 1, or 2, which is a way to measure how well a person can perform daily activities.
  • Must have certain laboratory values that show adequate function of the bone marrow, liver, and kidneys. This includes:
    • Hemoglobin level of at least 7.5 g/dL without recent blood transfusion.
    • Absolute neutrophil count (ANC) of at least 1.0 x 109/L.
    • Platelet count of at least 50 x 109/L if the bone marrow is heavily involved, otherwise at least 75 x 109/L.
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels no more than 2.5 times the upper limit of normal.
    • Total bilirubin level no more than 1.5 times the upper limit of normal, except in certain conditions.
    • Estimated creatinine clearance of at least 30 mL/min, which is a measure of kidney function.
    • Corrected serum calcium level no more than 13.5 mg/dL or free ionized calcium no more than 6.5 mg/dL.

Who cannot join the trial?

6 criteria

  • Patients who have a different condition than Multiple Myeloma cannot participate.
  • Patients who are not eligible for a transplant cannot participate.
  • Patients who have not been treated with the specific therapies mentioned in the study cannot participate.
  • Patients who are not within the specified age range cannot participate.
  • Patients who are not male or female cannot participate.
  • Patients who are considered part of a vulnerable population cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Daratumumab

    is a medication used to treat multiple myeloma. It works by targeting a specific protein on the surface of myeloma cells, helping the immune system to identify and destroy these cancer cells.

  • Bortezomib

    is a medication that helps treat multiple myeloma by interfering with the growth of cancer cells. It works by blocking a certain protein that cancer cells need to grow and multiply.

  • Lenalidomide

    is a medication used in the treatment of multiple myeloma. It helps the immune system attack cancer cells and also stops the growth of new blood vessels that tumors need to grow.

  • Dexamethasone

    is a type of steroid medication that is used to reduce inflammation and suppress the immune system. In the context of multiple myeloma, it helps to enhance the effects of other cancer treatments.

  • Teclistamab

    is an investigational medication being studied for its potential to treat multiple myeloma. It is designed to help the immune system recognize and attack myeloma cells.

  • Talquetamab

    is another investigational medication being tested for the treatment of multiple myeloma. It aims to target specific proteins on myeloma cells, helping the immune system to destroy them.

What is already known about the treatment

  • Daratumumab

    This medication is administered intravenously and is currently used in the treatment of multiple myeloma. It is well-documented in medical literature as an effective therapy for this condition. Daratumumab works by targeting a specific protein on the surface of myeloma cells, leading to their destruction. It is classified as a monoclonal antibody.

  • Bortezomib

    Administered via injection, bortezomib is used to treat multiple myeloma and is widely recognized in medical literature. It functions by inhibiting proteasomes, which are enzyme complexes that break down proteins in cells, leading to cancer cell death. Bortezomib is classified as a proteasome inhibitor.

  • Lenalidomide

    Taken orally, lenalidomide is used for treating multiple myeloma and is well-established in medical literature. It works by modulating the immune system and inhibiting the growth of cancer cells. Lenalidomide is classified as an immunomodulatory agent.

  • Dexamethasone

    This medication is administered orally or by injection and is used in the treatment of multiple myeloma. It is a well-known corticosteroid in medical literature, reducing inflammation and suppressing the immune response to help control cancer symptoms.

  • Teclistamab

    Administered via injection, teclistamab is currently being studied for its effectiveness in treating multiple myeloma. It is an investigational drug that targets specific proteins on cancer cells, aiming to enhance the immune system's ability to fight the disease. Teclistamab is classified as a bispecific antibody.

  • Talquetamab

    This medication is administered by injection and is under investigation for treating multiple myeloma. It works by engaging the immune system to target and destroy cancer cells. Talquetamab is classified as a bispecific antibody.

Investigated diseases

Multiple Myeloma – Multiple Myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and crowd out healthy blood cells, leading to problems such as anemia, infections, and bone damage. As the disease progresses, it can cause bone pain, fractures, and high levels of calcium in the blood. Patients may also experience kidney problems due to the accumulation of abnormal proteins produced by the cancerous cells. Over time, the disease can lead to weakened bones and increased susceptibility to infections. The progression of Multiple Myeloma varies among individuals, with some experiencing slow development and others facing more rapid advancement.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-505221-14-00Protocol codeEMN33Estimated enrolment240 patientsSponsorEmn Trial Office S.r.l. Impresa Sociale

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.